Since 1994, Pappas Ventures has been nurturing promising life sciences ideas and delivering superior results to investors and entrepreneurs alike.
Portfolio Highlights
Pappas Ventures News
-
Eric Linsley offers perspective on personalized medicine’s development
March 6, 2012 -
A Path Forward for the FDA
February 1, 2012
In the Spotlight
-
Arthur M. Pappas, Managing Partner
Art recently addressed the current FDA approval process in an article that appeared in the Venture Capital Journal entitled, “A Path Forward for the FDA.”
-
UltraGenyx Pharmaceutical
The European Medicines Agency has granted orphan drug designation for two lead product candidates, UX001 for Hereditary Inclusion Body Myopathy and UX003 for mucopolysaccharidosis type 7.